ClinicalTrials.gg
RecruitingNCT07484269PULSEUpdated Oct 30, 2026

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

An observational study in Metastatic Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to male participants. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 30, 2026Now RecruitingFirst site in Switzerland+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
753
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Started
2026
with 5 others
Observational
9 of 82
5 open now
Primary completion
2031-07
later than 23 of 24 live
Registered
79th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is one of 6 that started in 2026, is one of 9 observational ones, reaches primary completion later than 23 of the 24 other live ones, and was the 79th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Read the detailed description

This study is planned as a multicountry, non-interventional, longitudinal AI-enhanced digital registry that will leverage advanced data extraction technologies to efficiently generate RWD.

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • metastatic prostate cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with confirmed diagnosis of metastatic prostate cancer and treatment with at least one dose of lutetium (177Lu) vipivotide tetraxetan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years at index date

  • Diagnosis of mPC
  • PSMA positive
  • Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Exclusion criteria

Exclusion criterion:

  • Current or prior participation in an study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
753 participants (estimated)
Patient registry
No

Groups and cohorts

  • lutetium (177Lu) vipivotide tetraxetan

    Patients with metastatic prostate cancer who are treated with lutetium (177Lu) vipivotide tetraxetan over a five-year followup period

06

What researchers measure

Primary outcomes

  1. Proportion and number of patients who receive any given number of lutetium (177Lu) vipivotide tetraxetan cycles

    To describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among mPC patients

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

Secondary outcomes

  1. Patient demographics

    Profile of patient demographics (e.g., age, race)

    Time frame: Baseline

  2. Number of participants by clinical characteristics

    e.g., symptoms/physical signs of PC and metastasis, metastasis location)

    Time frame: Baseline

  3. real-world overall survival (rwOS)

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  4. median rwOS

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  5. Five-year rwOS

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  6. Real-world progression-free survival (rwPFS)

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  7. Median rwPFS

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  8. Five-year rwPFS

    Time frame: Date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the earliest of end of follow-up or last available EHR record, or the event date, up to 5 years

  9. PSA 30 response rate

    ≥ 30% decrease in PSA from date of lutetium (177Lu) vipivotide tetraxetan initiation \[index date\]

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  10. PSA 50 response rate

    ≥ 50% decrease in PSA from index date

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  11. PSA 90 response rate

    ≥ 90% decrease in PSA from index date

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  12. Time to treatment response

    Time to treatment response for PSA 30, PSA 50, and PSA 90

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  13. Best overall response (BOR)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  14. Overall response rate (ORR)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  15. Duration of response (DOR)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  16. Patients with evidence of adverse event of special interest (AESIs)

    Patients with evidence of AESIs, including, but not limited to, renal events, myelosuppression, dry eye, dry mouth, and second primary malignancies

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years

  17. Time interval between two consecutive cycles of lutetium (177Lu) vipivotide tetraxetan

    i.e., between first and second, second and third, third and fourth, fourth and fifth, and fifth and sixth cycles

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  18. Number and proportion of patients with a change in lutetium (177Lu)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  19. Number and proportion of patients with a change in frequency of lutetium (177Lu) vipivotide tetraxetan cycles

    Number and proportion of patients with a change in frequency of lutetium (177Lu) vipivotide tetraxetan cycles relative to the recommended frequency in the label

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  20. Time to first change in dose or frequency of lutetium (177Lu) vipivotide tetraxetan relative to the recommendations in the label

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  21. Time to discontinuation

    Persistence (time to discontinuation): time from the index date until the date of last dose of lutetium (177Lu) vipivotide tetraxetan administration

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  22. Number and proportion of newly diagnosed mPC patients treated with lutetium (177Lu) vipivotide tetraxetan as 1L

    1L: first line

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  23. Number and proportion of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan as 2L or 2L+

    2L: second line

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  24. Time to treatment initiation (TTI)

    time from diagnosis of mPC to the index date

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  25. Time to next treatment (TTNT)

    time from index date until the start date of the next treatment

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  26. Treatment free interval (TFI)

    aggregate time between the end date of one regimen/treatment and the start date of the next regimen/treatment for all treatments

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  27. Duration of treatment

    aggregate time of all treatment patterns from treatment/line initiation to discontinuation within each treatment (mean time on a given treatment for all patients)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  28. Number and proportion of patients discontinuing lutetium (177Lu) vipivotide tetraxetan documented by physician in the medical charts as discontinued.

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  29. Number and proportion of patients switching treatment

    Number and proportion of patients switching treatment, defined as discontinuation of lutetium (177Lu) vipivotide tetraxetan and initiation of new drug(s)

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  30. Number and proportion of patients who received each treatment prior to lutetium (177Lu) vipivotide tetraxetan administration since diagnosis of mPC

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

  31. Number and proportion of patients who received each treatment following initiation of lutetium (177Lu) vipivotide tetraxetan

    Time frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up or when applicable measured from mPC diagnosis to the index date, up to 5 years

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative SIte
    Basel, 4056, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jul 2031, 58 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Sep 30, 2026was Aug 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added — first site in Switzerland
Show site
  • Novartis Investigative SIte · Basel, Switzerland
Oct 30, 2026
Start date
Aug 1, 2026→Sep 30, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Switzerland
    Show site
    • Novartis Investigative SIte · Basel, Switzerland
    Start date Aug 1, 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07484269
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Sep 30, 2026
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion